SCHEMBL14979753

SCHEMBL14979753

C=CC(=O)Nc1ccc(C(=O)Nc2cccc(Nc3nccc(-c4cccnc4)n3)c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 12/20 0.79
ABL1 P00519 13/20 0.75
BCR P11274 11/20 0.75
PDGFRB P09619 8/20 0.75
SRC P12931 7/20 0.75
PRKCA P17252 4/20 0.75
PRKCD Q05655 3/20 0.75
PRKD3 O94806 1/20 0.75
PRKCG P05129 1/20 0.75
PRKCB P05771 1/20 0.75
PRKCH P24723 1/20 0.75
PRKCI P41743 1/20 0.75
PRKCE Q02156 1/20 0.75
PRKCQ Q04759 1/20 0.75
PRKCZ Q05513 1/20 0.75
PRKD1 Q15139 1/20 0.75
ABL2 P42684 2/20 0.74
MAPK8 P45983 2/20 0.73
MAPK9 P45984 2/20 0.73
MAPK10 P53779 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14979759 0.97 PDGFRA (0.77) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL14979760 0.93 PDGFRA (0.73) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL29644767 0.93 PDGFRA (0.73) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL20204854 0.91 ABL1 (0.72) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL20204860 0.89 MAPK8 (0.79) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL2317193 0.88 PDGFRA (1.00) PDGFRAABL1BCRPDGFRBPRKCA
SCHEMBL20998651 0.86 ABL1 (0.83) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL1430 0.86 ABL1 (1.00) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL9197 0.86 ABL1 (1.00) PDGFRAABL1BCRPDGFRBSRC
SCHEMBL11927817 0.85 PDGFRA (0.92) PDGFRAABL1BCRPDGFRBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153730-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-19 US disclosed
US-20210300911-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-30 US disclosed
US-10981903-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-04-20 US disclosed
US-20200087295-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-03-19 US disclosed
EP-3569598-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) Dana Farber Cancer Institute, Inc. (US) 2019-11-20 EP disclosed
US-20190248778-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-08-15 US disclosed
EP-2822935-B1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA FARBER CANCER INST INC (US) 2019-05-15 EP disclosed
US-20160368910-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-22 US disclosed
US-9382239-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-07-05 US disclosed
US-20140309249-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) Dana-Farber Cancer Intitute, Inc. (US) 2014-10-16 US disclosed
WO-2013074986-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981903-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) CNKSR1, MAPK1, MAP3K1 PDGFRA 2050/4885ABL1 1053/4885BCR 745/4885
US-20210300911-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 PDGFRA 2050/4885ABL1 1053/4885BCR 745/4885
US-20200087295-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 PDGFRA 2050/4885ABL1 1053/4885BCR 745/4885
US-20220153730-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 PDGFRA 2050/4885ABL1 1053/4885BCR 745/4885
US-20160368910-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 PDGFRA 2050/4885ABL1 1053/4885BCR 745/4885
US-20140309249-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 PDGFRA 2050/4885ABL1 1053/4885BCR 745/4885
US-20190248778-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 PDGFRA 2050/4885ABL1 1053/4885BCR 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.